Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2536651 | European Journal of Pharmacology | 2006 | 6 Pages |
Abstract
Up to now, baclofen (a GABAB receptor agonist) has been used for the treatment of severe spasticity unresponsive to oral antispasmodics. Although in humans it is usually administered at 2Â mg/ml, the dosage to be used in the treatment of other diseases is unknown. For this reason, it is important to determine the safe maximum dosage and toxicity at the clinically used concentration. Primary cortical neurons represent a useful model to test the safety of baclofen. We performed a colorimetric assay (MTT test) as well as electron microscopy investigations, to determine neuronal survival after the treatment with baclofen at a concentration of 2 and 4Â mg/ml. Our results demonstrated that, in our experimental model, neither concentration affected neuronal survival. Considering the above results, we can conclude that at the used concentrations, this drug is safe and its clinical use should be encouraged.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Alessandro Dario, Rossana Pisani, Simone Sangiorgi, Andrea Soragna, Marcella Reguzzoni, Marina Protasoni, Federico Pessina, Riccardo Fesce, Antonio Peres, Giustino Tomei,